EcoDrugPlus

Fms Related Receptor Tyrosine Kinase 3

Ensembl ID : ENSDORG00000010727
Gene Symbol: FLT3
3 Cross references
134 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 4

Ensembl ID : ENSDORG00000012877
Gene Symbol: FLT4
3 Cross references
198 Possible Orthologues:

Folate Hydrolase 1b

Ensembl ID : ENSDORG00000005050
Gene Symbol: FOLH1B
4 Cross references
211 Possible Orthologues:

Folate Receptor Alpha-Like

Ensembl ID : ENSDORG00000012556
Gene Symbol: LOC105984109
4 Cross references
204 Possible Orthologues:

Follicle Stimulating Hormone Receptor

Ensembl ID : ENSDORG00000006417
Gene Symbol: FSHR
3 Cross references
200 Possible Orthologues:

Free Fatty Acid Receptor 1

Ensembl ID : ENSDORG00000025362
Gene Symbol: FFAR1
4 Cross references
76 Possible Orthologues:

Fyn Related Src Family Tyrosine Kinase

Ensembl ID : ENSDORG00000000702
Gene Symbol: FRK
4 Cross references
217 Possible Orthologues:

Galactosidase Alpha

Ensembl ID : ENSDORG00000000854
Gene Symbol: GLA
4 Cross references
197 Possible Orthologues:

Galectin 1

Ensembl ID : ENSDORG00000005631
Gene Symbol: LGALS1
3 Cross references
331 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha1

Ensembl ID : ENSDORG00000010901
Gene Symbol: GABRA1
4 Cross references
201 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha2

Ensembl ID : ENSDORG00000011516
Gene Symbol: GABRA2
4 Cross references
201 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha3

Ensembl ID : ENSDORG00000003322
Gene Symbol: GABRA3
4 Cross references
198 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).